Home » Stocks » SWTX

Springworks Therapeutics, Inc. (SWTX)

Stock Price: $57.99 USD -1.49 (-2.51%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $57.86 -0.13 (-0.23%) Oct 30, 4:05 PM

Stock Price Chart

Key Info

Market Cap 2.78B
Revenue (ttm) n/a
Net Income (ttm) -68.24M
Shares Out 47.92M
EPS (ttm) -13.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $57.99
Previous Close $59.48
Change ($) -1.49
Change (%) -2.51%
Day's Open 59.40
Day's Range 57.00 - 59.90
Day's Volume 193,289
52-Week Range 17.02 - 63.31

More Stats

Market Cap 2.78B
Enterprise Value 2.49B
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 47.92M
Float 31.31M
EPS (basic) 2.82
EPS (diluted) -13.84
FCF / Share -1.44
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.15M
Short Ratio 5.80
Short % of Float 10.07%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 9.97
Revenue n/a
Operating Income -68.65M
Net Income -68.24M
Free Cash Flow -60.28M
Net Cash 291.80M
Net Cash / Share 6.09
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -17.31%
ROE -28.76%
ROIC -540.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(-1.02% downside)
Current: $57.99
Target: 57.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-59.24-18.49
Net Income-58.31-17.81
Shares Outstanding43.01341
Earnings Per Share-3.81-
Operating Cash Flow-47.44-14.17
Capital Expenditures-0.67-0.29
Free Cash Flow-48.11-14.46
Cash & Equivalents32846.19
Net Cash / Debt32846.19
Book Value322-19.37
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Springworks Therapeutics, Inc.
Country United States
Employees 66
CEO Saqib Islam

Stock Information

Ticker Symbol SWTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SWTX
IPO Date September 13, 2019


SpringWorks Therapeutics, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase IIb clinical trial for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in preclinical trials for the treatment of RRMM. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase Ib clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.